Supira’s technology features a novel low profile, high continuous flow design that aims to provide full hemodynamic support for high-risk percutaneous coronary interventions (HRPCI) and cardiogenic shock (CS) patients with a single device. Data from the Company’s First-in-Human trial to be presented as part of the Late-Breaking Clinical Research Session at SCAI 2023
Los Gatos, Calif., May 12, 2023 – Supira Medical, Inc., a Shifamed portfolio company, announced today that its next generation percutaneous ventricular assist device (pVAD) was selected following a highly competitive review process to be highlighted as part of this year’s European Association of Percutaneous Cardiovascular Interventions conference (EuroPCR) Innovator’s Day in Paris, France. Gagan Singh M.D., M.S., Director of Clinical Cardiovascular Research at University of California, Davis, will present on behalf of the company during the “Innovations in Heart Failure: Pumps, Remodeling and Monitoring” session beginning at 12:05 pm CET on Monday, May 15th in the Theatre Havane of the Palais de Congrès. Additionally, Supira Medical will be at booth M23 where PCR attendees can learn more about the system.